Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis Endovascular's vena cava filter gets FDA go-ahead:

This article was originally published in Clinica

Executive Summary

Cordis Endovascular, a Johnson & Johnson company, has received US FDA 510(k) clearance to market its 6F TRAPEASE permanent vena cava filter. Designed to prevent pulmonary embolism, the 6 French delivery system provides flexibility and support, minimising patient trauma and insertion site thrombosis. It has a symmetrical double-basket design, providing two levels of filtering and is the smallest, least invasive permanent vena cava filter available, claims the Warren, New Jersey-based company.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel